Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 6/20 | 0.46 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.40 |
| ▸ | CALCR | P30988 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31655138 | 0.98 | NMUR2 (0.43) | NMUR2NMUR1CXCR4OPRM1OPRD1 | |
| SCHEMBL31655366 | 0.96 | NMUR2 (0.43) | NMUR2NMUR1CXCR4OPRM1OPRD1 | |
| SCHEMBL28356821 | 0.95 | CXCR4 (0.47) | NMUR2NMUR1CXCR4OPRM1OPRD1 | |
| SCHEMBL31655163 | 0.93 | CXCR4 (0.47) | NMUR2NMUR1CXCR4RAMP3CALCR | |
| SCHEMBL29374733 | 0.91 | CXCR4 (0.45) | NMUR2NMUR1CXCR4 | |
| SCHEMBL30275450 | 0.91 | CXCR4 (0.46) | NMUR2NMUR1CXCR4OPRD1 | |
| SCHEMBL29864927 | 0.90 | OPRM1 (0.51) | NMUR2NMUR1CXCR4OPRM1OPRD1 | |
| SCHEMBL29864852 | 0.90 | OPRM1 (0.51) | NMUR2NMUR1CXCR4OPRM1OPRD1 | |
| SCHEMBL29864866 | 0.90 | OPRM1 (0.51) | NMUR2NMUR1CXCR4OPRM1OPRD1 | |
| SCHEMBL38650715 | 0.89 | CXCR4 (0.49) | NMUR2NMUR1CXCR4OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | CD47, HSP90AA1, HSF1 | NMUR2 3032/4885NMUR1 2929/4885CXCR4 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.